NCT01431521View on ClinicalTrials.gov

Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 26, 2011

Primary Completion Date

September 18, 2012

Study Completion Date

October 1, 2012

Conditions
Non-alcoholic Fatty Liver Disease
Interventions
DRUG

MK-4074 200 mg

2 x 100-mg capsules, orally, twice-daily (BID) for 4 weeks

DRUG

Placebo for MK-4074

2 x 100-mg capsules, orally, BID for 4 weeks.

DRUG

Pioglitazone hydrochloride 30 mg

1 x 30-mg tablet, orally, once daily for 4 weeks

DRUG

Placebo for pioglitazone hydrochloride

1 x 30-mg tablet, orally, once daily for 4 weeks

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01431521 - Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008) | Biotech Hunter | Biotech Hunter